Skip to main content

Advertisement

SpringerLink
Log in

Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy

  • Radiotherapy
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Aim

To evaluate the impact of moderately hypofractionated postoperative radiotherapy (RT) in prostate cancer (PCa).

Materials and methods

The data of 304 surgically resected PCa patients were analyzed. One hundred and five patients underwent adjuvant RT (aRT), 77 early-savage RT (esRT), and 123 salvage RT (sRT). Biochemical relapse-free survival (BRFS), progression-free survival (PFS) and toxicity were analyzed. A propensity score matching (PSM) was performed to account for potential confounders between aRT and esRT groups.

Results

The median follow-up was 33 months. Three-year BRFS and PFS were 82 and 85.2%, respectively, in the overall population. At the multivariate analysis, Gleason score and hormone therapy were factors independently correlated with BRFS and PFS. After PSM, there was no difference in BRFS and PFS between aRT and esRT patients. Severe toxicity was represented by grade 3 urinary incontinence (3.5%) and urgency (1%), and aRT correlated with increased any-grade acute toxicity. Severe grade 3 gastrointestinal late toxicity occurred in 1.3% of cases.

Conclusion

Postoperative moderately hypofractionated RT achieved acceptable disease control rate and demonstrated no increased or unexpected toxicity. Future prospective studies should evaluate the role of postoperative RT in patients with unfavorable disease characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

References

  1. European Commission. Estimates of cancer incidence and mortality in 2020, for all countries. Eur Com (2020). Online access on 2 April 2021. https://ecis.jrc.ec.europa.eu/explorer.php?$0-1$1-All$2-All$4-1,2$3-0$6-0,85$5-2004,2010$7-2$CRatesByRegistry$X0_10-ASR_EU_NEW

  2. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962. https://doi.org/10.1016/j.juro.2008.11.032

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–27 (Epub 2012 Oct 19)

    Article  Google Scholar 

  4. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol 66(2):243–250. https://doi.org/10.1016/j.eururo.2014.03.011 (Epub 2014 Mar 21)

    Article  PubMed  Google Scholar 

  5. Arcangeli S, Ramella S, De Bari B, Franco P, Alongi F, D’Angelillo RM (2016) A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective. Crit Rev Oncol Hematol 97:322–7. https://doi.org/10.1016/j.critrevonc.2015.09.005 (Epub 2015 Oct 9)

    Article  PubMed  Google Scholar 

  6. Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH (2014) Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 trial. Clin Oncol (R Coll Radiol) 26(6):348–352. https://doi.org/10.1016/j.clon.2014.02.012 (Epub 2014 Mar 27)

    Article  CAS  Google Scholar 

  7. Bruce JY, Lang JM, McNeel DG, Liu G (2012) Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol 10:716–722

    PubMed  Google Scholar 

  8. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, Williams SG, Brown C, Delprado W, Haworth A, Joseph DJ, Martin JM, Matthews JHL, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Wiltshire KL, Woo HH, Davis ID, Lim TS, Pearse M (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21(10):1331–1340. https://doi.org/10.1016/S1470-2045(20)30456-3

    Article  CAS  PubMed  Google Scholar 

  9. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O’Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, Røder MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396(10260):1413–1421. https://doi.org/10.1016/S0140-6736(20)31553-1

    Article  CAS  PubMed  Google Scholar 

  10. Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21(10):1341–1352. https://doi.org/10.1016/S1470-2045(20)30454-X

    Article  CAS  PubMed  Google Scholar 

  11. De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F (2018) Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiol Med 123(9):719–725. https://doi.org/10.1007/s11547-018-0890-7

    Article  PubMed  Google Scholar 

  12. Mazzola R, Cuccia F, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Pasinetti N, Salgarello M, Alongi F (2019) New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol 8(Suppl 5):S538–S541. https://doi.org/10.21037/tau.2019.12.34

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mahase S, Nagar H (2020) Hypofractionated postoperative radiotherapy for prostate cancer: Is the field ready yet? Eur Urol Open Sci 22:9–16. https://doi.org/10.1016/j.euros.2020.10.001

    Article  PubMed  PubMed Central  Google Scholar 

  14. European Association of Urology (EAU) prostate cancer guidelines. Online access on 2 April 2021. https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO_ESUR_ISUP_SIOG-Guidelines-on-Prostate-Cancer.pdf

  15. National Comprehensive Cancer Network (NCCN) prostate cancer guidelines. Online access on 2 April 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

  16. Ost P, Fonteyne V, Villeirs G, Lumen N, Oosterlinck W, De Meerleer G (2009) Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy forprostate cancer: clinical results in 104 patients. Eur Urol 56(4):669–675. https://doi.org/10.1016/j.eururo.2009.05.041

    Article  PubMed  Google Scholar 

  17. Ghadjar P, Hayoz S, Bernhard J et al (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33:4158–4166

    Article  CAS  Google Scholar 

  18. Cozzarini C, Montorsi F, Fiorino C et al (2009) Need for high radiation dose (>70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 75:966–974

    Article  Google Scholar 

  19. Zilli T, Jorcano S, Peguret N, Caparrotti F, Hidalgo A, Khan HG, Vees H, Weber DC, Miralbell R (2014) Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis. Acta Oncol 53(1):96–102. https://doi.org/10.3109/0284186X.2013.837584 (Epub 2013 Sep 13)

    Article  PubMed  Google Scholar 

  20. Beck M, Barelkowski T, Kaul D, Wecker S, Thieme AH, Zwahlen DR, Wust P, Aebersold DM, Budach V, Ghadjar P (2016) Role of dose intensification for salvage radiation therapy after radical prostatectomy. Front Oncol 1(6):48. https://doi.org/10.3389/fonc.2016.00048

    Article  Google Scholar 

  21. Dasu A, Toma-Dasu I (2012) Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963–974. https://doi.org/10.3109/0284186X.2012.719635 (Epub 2012 Sep 12)

    Article  PubMed  Google Scholar 

  22. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H (2018) Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol 8(6):354–360. https://doi.org/10.1016/j.prro.2018.08.002

    Article  PubMed  Google Scholar 

  23. Nicosia L, Mazzola R, Rigo M, Figlia V, Giaj-Levra N, Napoli G, Ricchetti F, Corradini S, Ruggieri R, Alongi F (2019) Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol 145(10):2547–2554. https://doi.org/10.1007/s00432-019-02983-3

    Article  PubMed  Google Scholar 

  24. Picardi C, Perret I, Miralbell R, Zilli T (2018) Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far? Cancer Treat Rev 62:91–96. https://doi.org/10.1016/j.ctrv.2017.11.004 (Epub 2017 Nov 14)

    Article  PubMed  Google Scholar 

  25. https://clinicaltrials.gov/ct2/show/NCT03274687

  26. Koerber SA, Katayama S, Sander A, Jaekel C, Haefner MF, Debus J, Herfarth K (2019) Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiat Oncol 14(1):122. https://doi.org/10.1186/s13014-019-1325-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781–1788. https://doi.org/10.1056/NEJM199912093412401

    Article  CAS  PubMed  Google Scholar 

  28. Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. Int J Radiat Oncol Biol Phys 54(5):1302–1310. https://doi.org/10.1016/s0360-3016(02)03052-3

    Article  CAS  PubMed  Google Scholar 

  29. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M (2007) EORTC radiation oncology group guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC radiation oncology group. Radiother Oncol 84(2):121–7. https://doi.org/10.1016/j.radonc.2007.07.017

    Article  PubMed  Google Scholar 

  30. Francolini G, Stocchi G, Detti B, Di Cataldo V, Bruni A, Triggiani L, Guerini AE, Mazzola R, Cuccia F, Mariotti M, Salvestrini V, Garlatti P, Borghesi S, Ingrosso G, Bellavita R, Aristei C, Desideri I, Livi L (2021) Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiol Med. https://doi.org/10.1007/s11547-021-01435-8

    Article  PubMed  PubMed Central  Google Scholar 

  31. Francolini G, Timon G, Matrone F, Marvaso G, Nicosia L, Ognibene L, Vinciguerra A, Trodella LE, Franzese C, Borghetti P, Jereczek-Fossa BA, Arcangeli S (2021) Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology). Clin Transl Oncol 23(12):2568–2578. https://doi.org/10.1007/s12094-021-02665-y

    Article  CAS  PubMed  Google Scholar 

  32. Alongi F, Cozzi L, Fogliata A et al (2013) Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Res 33(10):4537–4543

    PubMed  Google Scholar 

  33. Massaccesi M, Cilla S, Deodato F et al (2013) Hypofractionated intensitymodulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Res 33(6):2785–2789

    CAS  PubMed  Google Scholar 

  34. Lewis SL, Patel P, Song H et al (2016) Image guided Hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 94(3):605–611

    Article  Google Scholar 

  35. Macchia G, Siepe G, Capocaccia I et al (2017) Hypofractionated postoperative IMRT in prostate carcinoma: a Phase I/II Study. Anticancer Res 37(10):5821–5828

    PubMed  Google Scholar 

  36. Cuccia F, Mortellaro G, Serretta V, Valenti V, Tripoli A, Gueci M, Luca N, Lo Casto A, Ferrera G (2018) Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res 29(10):5053–5060. https://doi.org/10.2147/CMAR.S182016

    Article  Google Scholar 

  37. Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, Lo Russo M, Livi L (2020) Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int 125(3):417–425. https://doi.org/10.1111/bju.14924

    Article  CAS  PubMed  Google Scholar 

  38. Fersino S, Tebano U, Mazzola R et al (2017) Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer 15(4):e667–e673

    Article  Google Scholar 

  39. Kruser TJ, Jarrard DF, Graf AK, Hedican SP, Paolone DR, Wegenke JD, Liu G, Geye HM, Ritter MA (2011) Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117(12):2629–2636. https://doi.org/10.1002/cncr.25824

    Article  PubMed  Google Scholar 

  40. Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA (2008) Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 70(2):449–455. https://doi.org/10.1016/j.ijrobp.2007.06.042

    Article  CAS  PubMed  Google Scholar 

  41. Katayama S, Striecker T, Kessel K et al (2014) Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys 90(4):926–933

    Article  Google Scholar 

  42. Thompson IM, Valicenti RK, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190(2):441–449

    Article  Google Scholar 

  43. Chin S, Fatimilehin A, Walshaw R, Argarwal A, Mistry H, Elliott T, Logue J, Wylie J, Choudhury A (2020) Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure. Int J Radiat Oncol Biol Phys 107(2):288–296. https://doi.org/10.1016/j.ijrobp.2020.01.008

    Article  CAS  PubMed  Google Scholar 

  44. Nath SK, Sandhu AP, Rose BS et al (2010) Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78(2):435–441

    Article  Google Scholar 

  45. Azelie C, Gauthier M, Mirjolet C et al (2012) Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. Radiat Oncol 7:158

    Article  Google Scholar 

  46. Wu WJ, Potters L (2017) Counterpoint: early salvage vs adjuvant radiotherapy for high-risk prostate cancer: the data for adjuvant radiotherapy remain strong. Oncology 31(10):750

    PubMed  Google Scholar 

  47. Casas F, Valduvieco I, Oses G, Izquierdo L, Archila I, Costa M, Cortes KS, Barreto T, Ferrer F (2019) Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival. Clin Transl Oncol 21(3):355–362. https://doi.org/10.1007/s12094-018-1931-3

    Article  CAS  PubMed  Google Scholar 

  48. Ippolito E, Cellini N, Digesù C, Cilla S, Mantini G, Balducci M, Di Lallo A, Deodato F, Macchia G, Massaccesi M, Mattiucci GC, Tagliaferri L, Piermattei A, Cuscunà D, Morganti AG (2013) Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial. Urol Oncol 31(1):87–92. https://doi.org/10.1016/j.urolonc.2010.10.005

    Article  PubMed  Google Scholar 

  49. Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N (2014) Higher-than-expected severe (Grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66(6):1024–1030. https://doi.org/10.1016/j.eururo.2014.06.012

    Article  PubMed  Google Scholar 

  50. Alongi F, Fersino S, Giaj Levra N, Mazzola R, Ricchetti F, Fiorentino A, Ruggieri R, Malfatti V, Cavalleri S, Salgarello M (2015) Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496-500. https://doi.org/10.1097/RLU.0000000000000841

    Article  PubMed  Google Scholar 

  51. Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L, Livi L, Magrini SM, Salgarello M, Alongi F (2020) Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer S1558–7673(20):30191–30199. https://doi.org/10.1016/j.clgc.2020.08.002

    Article  Google Scholar 

  52. Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D’agostino G, Corradini S, Alongi F, Scorsetti M (2020) Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol 196(3):213–221. https://doi.org/10.1007/s00066-019-01523-9

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, Verona, Italy

    Luca Nicosia, Rosario Mazzola, Claudio Vitale, Francesco Cuccia, Vanessa Figlia, Niccolò Giaj-Levra, Francesco Ricchetti, Michele Rigo, Ruggiero Ruggeri & Filippo Alongi

  2. Urology Division, Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy

    Stefano Cavalleri

  3. University of Brescia, Brescia, Italy

    Filippo Alongi

Authors
  1. Luca Nicosia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosario Mazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudio Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Cuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vanessa Figlia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niccolò Giaj-Levra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Ricchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michele Rigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ruggiero Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stefano Cavalleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Filippo Alongi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Cuccia.

Ethics declarations

Conflict of interest

All the authors have no competing interests.

Ethical standard

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nicosia, L., Mazzola, R., Vitale, C. et al. Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. Radiol med 127, 560–570 (2022). https://doi.org/10.1007/s11547-022-01479-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-022-01479-4

Keywords

Search

Navigation